

Suven Life Sciences to Present Key Advances in Alzheimer's and Neuropsychiatric Clinical Candidates at AAIC® 2025, Toronto, Canada.

Hyderabad, India, 28-July-2025 – Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, today announced it is presenting three virtual poster presentations at the Alzheimer's Association International Conference® (AAIC®) 2025, taking place during July 27–31 in Toronto, Canada, and Online. AAIC is the largest and most influential international conference dedicated to advancing science related to Dementia and associated disorders.

Presentations:

Clinical and Non-Clinical Evidence Supporting the Development of Masupirdine (SUVN-502) for the Management of Agitation in Alzheimer's Disease.

This poster presents compelling clinical and non-clinical findings supporting Masupirdine, a pure serotonin 5-HT₆ receptor antagonist, as a promising candidate for managing agitation—an unmet need in Alzheimer's disease treatment.

Non-clinical Efficacy and Safety of SUVN-L3307032, a Muscarinic M4 Positive Allosteric Modulator (M4 PAM), for the Treatment of Neuropsychiatric Symptoms.

Highlighting non-clinical data, this presentation evaluates the efficacy and safety of SUVN-L3307032, a potent and selective M4 PAM, demonstrating its potential for addressing neuropsychiatric symptoms such as psychosis and agitation without cholinergic side effects.

Update on the Development of SUVN-I6107: A True Positive Allosteric Modulator of the Muscarinic M1 Acetylcholine Receptor for the Treatment of Dementia.

This update outlines the pharmacological profile, development status, and translational potential of SUVN-I6107, a highly selective M1 PAM, for the treatment of dementia.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase 3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase 2 study for EDS completed; Phase 2 study for Cataplexy and pivotal Phase 3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase 2a study completed; Double blind randomized Placebo-controlled Phase 2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase 2 study in planning), SUVN-I6107 for cognitive disorders (Phase 1 study ongoing). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

For more information, please visit our website <http://www.suven.com>

Risk Statement: Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad - 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com